Paul Miranda, MD

Board-Certified in Family Medicine · Emergency Physician · Obesity Medicine Association member

I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.

Medically reviewed by Paul Miranda, MD

If you’re in Chattanooga comparing Ro to a compounded semaglutide clinic, you’ve probably already noticed the two quotes don’t look like they’re for the same drug. One is close to $500 a month. The other is under $225. I’m Dr. Paul Miranda, board-certified, practicing telehealth from right here in Chattanooga, and I personally review every chart before a patient starts semaglutide at Summit Metabolic Health. Here’s the honest comparison Ro’s pricing page won’t walk you through.

Ro exited compounded GLP-1s this year. After its June 30 pricing cliff, Ro sells branded-only semaglutide — meaning Wegovy or Ozempic at the manufacturer’s list price, routed through Ro’s platform — for roughly $448 to $498 a month, all-in. There’s no transparent lower tier. You either pay the branded rate or you leave.

That’s not a criticism of the drug. It’s a fact about the bill. A patient who started with Ro during its compounded-pricing era and is still a Ro patient today is very likely paying two to three times what they budgeted for, because the company’s entire low-cost option disappeared in one pricing change. If you’re currently on Ro and haven’t checked your last invoice against your first one, that’s worth doing before you read any further.

Here’s the part almost nobody explains clearly: semaglutide is semaglutide. The active ingredient driving weight loss and the cardiovascular benefit below is identical whether it’s dispensed from a brand-name pen under the Wegovy label or compounded by a licensed 503A pharmacy under a physician’s prescription. What changes is the manufacturing and distribution pathway — not the molecule your body receives.

Branded semaglutide carries a manufacturer’s patent, a sales and marketing budget, and now, in Ro’s case, a direct-to-consumer markup layered on top. Compounded semaglutide is prepared to order by a licensed pharmacy from the same active pharmaceutical ingredient, without the branded packaging or the ad spend. That’s the entire reason Summit’s compounded program runs $135 to $225 a month instead of $448 to $498. You’re not paying less for less drug. You’re paying less for less overhead between the pharmacy and you.

I go deeper on how compounded sourcing actually works, pharmacy by pharmacy, in Compounded Semaglutide vs. Ozempic, if you want the fuller breakdown before you switch.

What compounding doesn’t change is the regulatory floor. A licensed 503A pharmacy still has to source its active pharmaceutical ingredient from a registered, inspected facility and compound to a physician’s written prescription — it isn’t a med spa mixing something in a back room. That’s part of why the chart review matters as much as the pharmacy: the prescription has to be written by someone who’s actually looked at your history, not auto-generated by a form.

The data behind semaglutide doesn’t care which bottle it came from, because it’s the same drug. In STEP 1 (Wilding et al., NEJM, 2021), patients on semaglutide 2.4mg lost a mean of 14.9% of body weight at 68 weeks, against 2.4% on placebo. That’s a real, measured difference — a trial average, not a promise about any individual outcome.

The second trial matters more than most patients realize. SELECT (Lincoff et al., NEJM, 2023) enrolled patients with established cardiovascular disease and found semaglutide cut major adverse cardiac events — heart attack, stroke, cardiovascular death — by 20%, independent of whether the patient had diabetes. I work in the ER. I pay attention to that number specifically, because it means this drug’s value isn’t only on the scale. Neither trial asked whether the semaglutide came from a pen with a brand name on it. The molecule did the work.

Ro’s model is async: you fill out a questionnaire, and an NP or PA signs off, often without ever speaking to you. That can be fast. It is not the same as a physician reading your actual chart. I read every chart myself at Summit — not a form run through software, not a queue a nurse clears between other patients. I look at your history, your prior medications, your labs if you have them, and I decide your starting dose and titration schedule based on you, not a default algorithm every patient on the platform gets.

A checkbox you click yourself is not the same as a physician reviewing it. That gap doesn’t show up on day one. It shows up when your dose needs adjusting, when a side effect needs a real answer instead of a canned reply, or when something in your history should have changed the plan and nobody who understood it ever looked. I’ve written more on where this specific gap costs patients in Is Telehealth Semaglutide Legit? and in Physician-Supervised Care vs. the Telehealth Mill Model.

Ro is a national company with no address you can drive to and no physician who knows your city. I’m local. Care at Summit is telehealth, but the physician running it lives and works in Chattanooga — I see the same ER that your neighbors end up in when something goes wrong with a medication nobody adjusted. That’s not a marketing line. It’s the actual difference between a subscription built to scale to every zip code in the country and a practice built around a smaller number of charts I can read closely.

A national DTC company can’t offer you same-area, in-person accountability, because that was never the product. The product is volume. Summit’s model is the opposite: fewer patients per physician, more attention per chart, and a doctor who’s answerable to the same community you live in.

If something goes wrong with your dose — nausea that won’t quit, a side effect that doesn’t match what the app’s FAQ describes — you’re not reopening a support ticket and waiting for whichever clinician is on shift that day. You’re reaching the same physician who set your starting dose in the first place, and who has the actual history to know whether what you’re describing is expected or worth adjusting.

Ro’s June 30 cliff should be a warning about more than just Ro. Any DTC telehealth company that offers a teaser rate on compounded medication can end that rate the same way Ro did — in one pricing email, with no negotiation. Summit never ran a compounded teaser rate that we then pulled. Our compounded semaglutide pricing is flat and descending as your dose comes down, not set up to spike once you’re dependent on the medication to keep going.

That matters for the exit, too. I keep patients at the lowest effective dose for as long as possible, target a controlled pace of weight loss rather than the fastest number the drug allows, and taper the dose down at goal weight instead of leaving you at a cliff where the prescription just stops. None of that works if the price itself is also a cliff waiting to drop on you. You can read more about how Summit approaches GLP-1 therapy generally on the Summit blog.

The honest caveat: trial averages are trial averages, not a guarantee for you specifically, and semaglutide still needs monitoring regardless of where it’s sourced. But the price difference between Ro’s post-cliff rate and a compounded program reviewed by a physician in your own city is not a close call. If you want a straight answer on what you’d actually pay, apply at summitmetabolichealth.com/apply. </content>